GENFIT

GENFIT is a late-stage biopharmaceutical company headquartered in Loos, France, dedicated to improving the lives of patients with rare, life-threatening liver diseases. The company leverages its deep scientific heritage in nuclear receptor research to develop therapeutic and diagnostic solutions for conditions with high unmet medical needs, such as Acute-on-Chronic Liver Failure (ACLF). Beyond its therapeutic pipeline, GENFIT has established a diagnostic franchise focused on liver disease monitoring. The company has successfully developed elafibranor (marketed as Iqirvo® by partner Ipsen), which received regulatory approvals in the U.S., Europe, and the UK for the treatment of Primary Biliary Cholangitis (PBC).